Although Medicis had planned to rebrand the product as ‘Reloxin’, they ultimately decided to retain its original European name, Dysport. (pronounced Diss-port).

Botox and Dysport both perform the same basic function – neuromuscular blocking to relax and prevent wrinkles. Dysport is said to be more diluted than Botox and perhaps, more cost effective for providers.

The April 30th announcement coincided with a 3 percent drop in Allergan’s (maker of Botox) shares, as Medicis shares jumped 14 percent. Analysts and industry professionals expect Dysport to carry a slightly lower price tag than Botox, and speculate that it may capture 30 percent of the market.